ReviewJournal of neurology2024
Primary central nervous system lymphoma.
Review in Journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Efficacy and safety of rituximab in the treatment of primary central nervous system lymphoma: A meta-analysis and systematic review of 1,388 patients.Oncology letters · 2026Article
- Primary central nervous system lymphoma-current standards and recent developments.Neuro-oncology practice · 2026Review
- Survival Outcomes and Prognostic Factors in Patients With Primary Central Nervous System Low-Grade B-Cell Lymphoma: A Population-Based Cohort Study.Cancer medicine · 2026Article
- Case Report: Primary Central Nervous System Lymphoma With "Wine Glass" Sign Presenting as Somnolence and Fatigue.The American journal of case reports · 2026Article
- Microstructure mapping with time-dependent diffusion MRI differentiates primary central nervous system lymphoma from glioblastoma.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- A case report: primary central nervous system lymphoma misdiagnosed as neuromyelitis optica.BMC neurology · 2026Article
- Educational and regional differences in population-based incidence and survival of primary central nervous system lymphoma in Finland.BMC cancer · 2026Article
- Primary large B-cell lymphoma of the central nervous system mimicking inflammatory myelitis at initial presentation.Journal of clinical and experimental hematopathology : JCEH · 2025Article
- Acalabrutinib May Offer a New Therapeutic Approach for Consolidation and Maintenance of Primary CNS Lymphoma with Expression of MYD88 and CD79B Gene Variants: A Case Report and Literature Review of Primary CNS Lymphoma in the BTKi Era.International journal of molecular sciences · 2025Review
- Lymphoproliferative Disorders Mimicking Rheumatologic Disease: A Clinical Reasoning Perspective.Current allergy and asthma reports · 2025Review
- Review
- Morphological, immunophenotypic and neuroradiological characteristics of primitive B-large cell diffuse lymphoma of the central nervous system: A retrospective cohort analysis.Oncology letters · 2025Article
- Management of primary central nervous system lymphoma and coexisting heart failure with reduced ejection fraction: a narrative review.Cardio-oncology (London, England) · 2025Review
- Multiparametric MRI for differential diagnosis of primary central nervous system lymphoma and atypical glioblastoma: an analysis incorporating DWI, DCE-MRI, and contrast agent preload DSC-PWI.BMC medical imaging · 2025Article
- Post-marketing surveillance of tirabrutinib in 189 patients with r/r primary central nervous system lymphoma.Future oncology (London, England) · 2025Observational
- Blood-brain barrier crossing biopolymer targeting c-Myc and anti-PD-1 activate primary brain lymphoma immunity: Artificial intelligence analysis.Journal of controlled release : official journal of the Controlled Release Society · 2025Article
- Clinical impact and safety of brain biopsy in unexplained central nervous system disorders: a real-world cohort study.Annals of clinical and translational neurology · 2025Article
- Relapsed or refractory central nervous system lymphoma successfully treated by glofitamab combined with lenalidomide.Frontiers in oncology · 2025Article
- Primary large B-cell lymphoma of the central nervous system misdiagnosed as autoimmune encephalitis: a case report.Frontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary central nervous system lymphoma (PCNSL) is a rare type of non-Hodgkin lymphoma (NHL) manifesting in the brain, spinal cord, cerebrospinal fluid and/or eyes, in the absence of systemic manifestations. With an increasing incidence and a 30% 5-year overall survival if promptly treated, timely diagnosis and subsequent treatment is paramount. The typical MRI appearance for PCNSL is a solitary or multiple T2-hypointense, homogeneous gadolinium-enhancing lesion with restricted diffusion. Dexamethasone treatment might compromise and delay the diagnosis. Hallmark of treatment is induction with intravenous high-dose methotrexate consisting polychemotherapy followed by consolidation treatment. Consolidation treatment consists of either whole brain radiotherapy (WBRT) or autologous stem cell transplantation (ASCT). Given the (cognitive) side effects of WBRT, ASCT is increasingly being used as the first choice of treatment.
Indexed as
Identifiers
38112784What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.